Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC
Approximately half of all patients with early lung cancer experience cancer recurrence following surgery
Read More
Apr 19, 2024 | Regulatory, News
Approximately half of all patients with early lung cancer experience cancer recurrence following surgery
Read MoreThe Paddington site will serve as one of the company’s three global hubs
Read MoreThe infectious condition affects up to one in three people globally in their lifetimes
Read MoreThe three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma
Read MoreThe selected candidate can be developed as a monotherapy, combination therapy or both
Read MoreThe chronic neurological condition affects more than 2.8 million people worldwide
Read MoreApproximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease
Read MoreThe aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year
Read MoreCKD is a progressive condition that affects nearly 850 million people worldwide
Read MoreApr 17, 2024 | News, Regulatory
Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050
Read MoreApproximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease
Read MoreApproximately 25 people per million worldwide are diagnosed with IgAN every year
Read MoreAccount Specialist - Respiratory - Kent & Medway
Market Access Business Manager - Advanced Wound Care - North
Key Account Manager - Urology - East Anglia, Beds & Bucks
Therapy Development Specialist - Greater London & East Anglia